Trial Profile
A Multicenter, Open-label, Randomized, Controlled, Two-arm Study to Assess Compliance With Daily Tablet Intake of Women on Treatment With the Oral Contraceptive SH T00186D/BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function Over 12 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare
- 25 Jul 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Sep 2011 Planned end date changed from 1 Sep 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.